Pharmaceutical sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Clinical Trials
Studies where CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 35Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
HER2-Negative Advanced Breast Cancer
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.
- Trial name
- NCT07805135
- Testing
- HB1801, Docetaxel (Taxotere®)
- Volunteers
- 430 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Influenza
A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of SYH2085 tablets compared with placebo in Chinese adult participants with uncomplicated influenza.
- Trial name
- NCT07798193
- Testing
- SYH2085
- Volunteers
- 213 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Myasthenia Gravis
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
This study is a single-arm, open, 2-stage (dose-escalation phase and dose-expansion phase), multi-center, phase I clinical trial to evaluate the safety and tolerance of SYS6020 injection in the participants with refractory…
- Trial name
- NCT06688435
- Testing
- SYS6020 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine hydrochloride Enteric-coated Tablets in Healthy Participants.The study is composed of 2 parts.
- Trial name
- NCT07756996
- Testing
- Ammoxetine hydrochloride Enteric-coated Tablets(new formulation), Ammoxetine hydrochloride Enteric-coated Tablets(Phase III formulation)
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants, Participants With Moderate Renal Impairment
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
This study is a single-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical trial evaluating the pharmacokinetic characteristics of ammoxetine hydrochloride enteric-coated tablets in participants…
- Trial name
- NCT07694869
- Testing
- ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants, Participants With Mild Hepatic Impairment
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function
Use these resources to provide understandable information about this study to patients, families, and health care providers:This study is a multi-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical…
- Conditions
- Healthy Participants, Participants With Mild Hepatic Impairment, Participants With Moderate Hepatic Impairment
- Trial name
- NCT07694843
- Testing
- ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Malignant Tumors
SYH2095 for Advanced Malignant Tumors: Phase I Study
This is an open-label, multicenter Phase 1 first-in-human trial of SYH2095, a selective KAT6A/B inhibitor. The trail contains two segments: Part 1A dose escalation and Part 2A cohort expansion.
- Trial name
- SYH2095-001 (NCT07692776)
- Testing
- SYH2095
- Where
- China
- Volunteers
- 140 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Epithelioid Hemangioendothelioma
A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients with Progressive or Symptomatic Epithelioid Hemangioendothelioma.
- Trial name
- NCT07684287
- Testing
- Sirolimus for injection (Albumin-bound)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
- Trial name
- NCT07623824
- Testing
- SYHX2008, Sandostatin LAR®
- Volunteers
- 154 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.